Nih Coq10 And Cancer 2018 PdfBy Fortun T. In and pdf 27.03.2021 at 13:39 4 min read
File Name: nih coq10 and cancer 2018 .zip
You have many choices to make about your cancer treatment. One choice you might be thinking about is complementary and alternative medicine CAM.
- Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
- Coenzyme Q10 (PDQ®)–Patient Version
- What are the benefits of CoQ10?
Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
To better evaluate the efficacy of CoQ10 on the inflammatory markers in breast cancer patients, we conducted a clinical study of patients with breast cancer undergoing tamoxifen therapy. CoQ10 serves as an antioxidant and inhibits oxidation caused by reactive oxygen species. The aim of the current study was to assess the effect of coenzyme Q10 supplementation on serum levels of interleukin 6, 8, and vascular endothelial growth factor VEGF in patients with breast cancer undergoing tamoxifen therapy by a double-blind, placebo-controlled, randomized clinical trial.
In the study, 30 breast cancer patients and 29 healthy subjects were randomized into four groups. Two groups of intervention received mg CoQ10, and two control groups took placebo once a day for 2 months. Blood draws were obtained at baseline and at the end of the study. The data of the 59 participants were analyzed.
Although the downward trend was evident, CoQ10 supplementation did not reveal any significant effect on serum VEGF concentration. The group of patients who received supplements showed the most reduction in serum levels of cytokines among other groups. CoQ10 supplementation could be effective in ameliorating inflammatory cytokine levels, thereby reducing the consequences of inflammation caused by breast cancer. To generalize the results, larger and longer intervention studies with higher safe doses are needed and should take account of possible costs and harms as well as benefits registration number: IRCTN1.
Coenzyme Q10 CoQ10 is a protective lipophilic molecule, synthesized in human cells under the control of HMG CoA reductase 1 and plays a vital role in the production of ATP as an electron carrier in the respiratory chain.
CoQ10 has the potency of conferring protection from reactive oxygen species ROS , improves the function of protein and enzymes, and reconstructs antioxidants such as vitamin E, vitamin C, and lipoic acid after protecting DNA, lipids and other proteins from oxidative damage.
In addition, CoQ10 preserves the brain and other neural tissues from damages caused by free radicals. Breast cancer BC is the most prevalent female cancer and the major cause of death in middle-aged women. One of the most common drugs used to treat breast cancer is tamoxifen — a selective estrogen receptor modulator.
Cytokines have both tumor-promoting and inhibitory effects on breast cancer growth depending presumably on their relative concentrations and the presence of other moderating factors. Cytokines play a significant role in immune system management. IL-6 is a pleiotropic cytokine with noticeably tumor-promoting and tumor-inhibitory effects. In addition, IL-8 seems to have a remarkable capability to functions as a prognostic cancer biomarker via autocrine and paracrine.
Moreover, angiogenesis is crucial for tumor growth. VEGF is one of the most potent angiogenic cytokines. Heer et al have shown that serum VEGF has a much higher sensitivity The reduction of CoQ10 serum levels in BC patients is associated with less accurate prediction. One of the CoQ10 anti-inflammatory properties is performed by reducing inflammatory cytokines' secretion.
In our literature review, no clinical trials have been found to support the efficacy of CoQ10 alone in BC patients. In this randomized double-blind placebo-controlled clinical trial, women diagnosed as breast cancer patients with positive estrogen receptor were first assessed for eligibility and 30 patients met the inclusion criteria. Exclusion criteria were as follows: metastasis and total or partial mastectomy. Informed consent was obtained from all subjects with a due explanation of the study.
The patients were randomly allocated into two groups of intervention and control. Subjects in the intervention group Group 1.
A received placebo for 2 months. Placebo capsules were the same color and shape as the supplements. The subjects were advised to take the supplements within meals. Compliance was checked by counting the number of tablets handed out to the patients and recollected at the end of the study. The safety of the dose and duration of the study had been proved by the preceding studies.
B and placebos group 2. B , respectively. Blood samples were collected after 8—12 hrs of overnight fasting, in the beginning and at the end of the study, respectively.
All biochemical assessments were performed by a skilled assessor who was blind to the group assignment. All the subjects were commanded by a dietitian to maintain a 3-day dietary record, including two weekdays and one weekend day before and after the end of the study period. Dietary energy and nutrient intake were analyzed by Nutritionist IV software.
The normality of the distribution of the variables was evaluated using the Shapiro—Wilk test. Chi-square and Kruskal—Wallis H -tests were employed to assess baseline group differences in categorical and continuous variables.
Paired sample t -test was assessed the differences in each group of mean serum levels of coenzyme Q10 before and after the intervention. A total of 59 subjects were randomized in this trial Figure 1.
Baseline characteristics for all participants are summarized in Table 1. Patient features did not differ significantly between the treatment groups. None of the participants in the study had specific illnesses such as diabetes, hypertension, and thyroid disorders. Fourteen percent, with the exception of one person in each group with regular menstrual cycles.
All patients were at stage 1 or 2 of breast cancer. One hundred twenty-two subjects were included in the study. After the exclusion of 63 subjects due to unwillingness, travelling, medication alteration, and susceptibility to CoQ10, 30 breast cancer patients and 29 healthy persons remained and randomized to four groups.
Fifteen breast cancer patients and 14 healthy subjects took the CoQ10 supplement and 15 breast cancer patients and 15 healthy subjects took the placebo. Serum samples were sent to the laboratory for evaluation of inflammatory factors before and 8 weeks after the intervention. In addition, dietary intake of energy and macronutrients was assessed before and after supplementation.
No difference was observed between groups at baseline and no change was detected at the end of 2 months. The average compliance was estimated to be approximately CoQ10 serum levels were measured at baseline and following the 8 weeks of therapy.
These data are summarized in Table 2. As can be seen, patients had lower levels of CoQ10 than healthy people. IL-6 serum levels were high in four groups at baseline. Hence, paired comparisons of IL-6 serum levels between Group 1. Also, paired comparisons of IL-8 serum levels between Group 1.
A, Group 1. A and Group 1. This trial demonstrated that CoQ10 supplementation for 8weeks in breast cancer patients led to a significant decrease in IL-8 and IL-6 concentrations compared to placebo.
Moreover, a non-significant decline was observed in VEGF in four groups. Although the reduction was larger in the supplemented groups than in placebo groups, the difference between the groups was not significant. The circulating levels of CoQ10 associated with breast cancer risk. SWHS study, with a relatively larger sample size and longer follow-up time, shows an inverse association for plasma CoQ10 levels with breast cancer risk in Chinese women. Despite the conflicting effects of IL-6 on breast cancer cells exhibited in many in vitro studies, there is a growing number of trials indicating that the up-regulated serum IL-6 level which demonstrates high IL-6 serum level is a negative prognostic indicator in breast cancer patients.
Interleukin 8 could be an essential factor in breast cancer and could influence the efficiency of the treatment by tamoxifen. Therefore, IL-8 and IL-8 receptors are crucial. Proliferation of endothelial cells and promotion of blood vessel permeability is caused by VEGF.
The effects of CoQ10 on oxidative stress and inflammation in other diseases are examined by many researchers, but the results are not consistent. In studies that have been conducted on rheumatoid arthritis 19 and hepatocellular carcinoma 20 and non-alcoholic fatty liver diseases, 21 patients showed no significant reduction in IL-6 between groups.
On the other hand, Michael W. Surprisingly IL-6 levels at 12, 24, 48, and 72 hrs were significantly higher in patients receiving ubiquinol when compared to the placebo group. Antioxidant activity is the most prominent biological characteristic of CoQ10, which can scavenge free radicals, also reform the antioxidant defense system by reducing oxidized antioxidants. However, the activation cascade could be blocked by antioxidants such as Q The first study conducted on CoQ10 supplementation efficacy individually was successful in inflammatory status amelioration in breast cancer patients.
Further studies as larger and longer clinical trials with higher safe doses are suggested to generalize results. Karbalai for his contribution in laboratory analyses, and Mrs. Maraghi for cooperation in conducting the statistical analysis of data.
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Signed informed consent was obtained from all individual participants included in the study. All authors contributed to data analysis, drafting, and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work. National Center for Biotechnology Information , U. Ther Clin Risk Manag.
Published online Dec 4. Author information Article notes Copyright and License information Disclaimer. Received Oct 16; Accepted Nov This work is published and licensed by Dove Medical Press Limited. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4. This article has been cited by other articles in PMC.
Abstract Background To better evaluate the efficacy of CoQ10 on the inflammatory markers in breast cancer patients, we conducted a clinical study of patients with breast cancer undergoing tamoxifen therapy.
Coenzyme Q10 (PDQ®)–Patient Version
NCBI Bookshelf. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of coenzyme Q10 in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This cancer information summary provides an overview of the use of coenzyme Q 10 in cancer therapy. The summary includes a history of coenzyme Q 10 research, a review of laboratory studies , and data from investigations involving human subjects. Although several naturally occurring forms of coenzyme Q have been identified, Q 10 is the predominant form found in humans and most mammals, and it is the form most studied for therapeutic potential.
Coenzyme Q10 is a dietary supplement, and use of it as a treatment for Get detailed information about Coenzyme Q10 use in cancer in this summary for clinicians. a policy statement of NCI or the National Institutes of Health (NIH). ; NBK April 21, ; NBK September 30,
What are the benefits of CoQ10?
Oxidative damage in endothelial cells is proposed to play an important role in endothelial dysfunction and atherogenesis. We previously reported that the reduced form of coenzyme Q10 CoQ 10 H 2 effectively inhibits oxidative stress and decelerates senescence in senescence-accelerated mice. Here, we treated human umbilical vein endothelial cells HUVECs with H 2 O 2 and investigated the protective effect of CoQ 10 H 2 against senescence, oxidative damage, and reduction in cellular functions. CoQ 10 H 2 prevented apoptosis and reductions in mitochondrial function and reduced migration and tube formation activity of H 2 O 2 -treated cells.
The burden of cardiovascular and metabolic diseases is increasing with every year. Although the management of these conditions has improved greatly over the years, it is still far from perfect. With all of this in mind, there is a need for new methods of prophylaxis and treatment. Coenzyme Q10 CoQ10 is an essential compound of the human body.
Coenzyme Q CoQ is an essential component of the mitochondrial electron transport chain and an antioxidant in plasma membranes and lipoproteins. It is endogenously produced in all cells by a highly regulated pathway that involves a mitochondrial multiprotein complex. Here, we review the current knowledge of CoQ 10 biosynthesis and primary CoQ 10 deficiency syndrome, and have collected published results from clinical trials based on CoQ 10 supplementation. There is evidence that supplementation positively affects mitochondrial deficiency syndrome and the symptoms of aging based mainly on improvements in bioenergetics.
To better evaluate the efficacy of CoQ10 on the inflammatory markers in breast cancer patients, we conducted a clinical study of patients with breast cancer undergoing tamoxifen therapy.
Survival rates among breast cancer patients and the number of patients living with treatment side effects have improved, leading to increased focus on quality of life QOL. The objective of this study was to determine the efficacy of CoQ 10 on QOL scores among breast cancer patients in Iranian undergoing tamoxifen therapy. Thirty breast cancer patients were randomized into two groups. The first group received mg CoQ 10 , and the second group took fplacebo once a day for 8 weeks. Also, physical activity of patients was assessed with the IPAQ questionnaire and dietary intake determined by a 3-day dietary record.
Как он поведет машину, если они все же доберутся до. И тут в его памяти зазвучал голос одного из преподавателей Корпуса морской пехоты, подсказавший ему, что делать. Применив силу, говорил этот голос, ты столкнешься с сопротивлением. Но заставь противника думать так, как выгодно тебе, и у тебя вместо врага появится союзник. - Сьюзан, - услышал он собственный голос, - Стратмор - убийца.
Это странное имя, по-видимому, не вызвало у женщины каких-либо ассоциаций. Она извинилась, предположила, что Беккер перепутал агентство, и, наконец, положила трубку. Первая попытка закончилась неудачей. Нахмурившись, Беккер набрал второй номер.